Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Carolina Cataract & Laser Center (CCLC) announced on April 29 that David Vroman, M.D., is the first physician in South ...

Please provide your email address to receive an email when new articles are posted on . In the world of technology, disruptors are sought-after and celebrated. When Roy S. Rubinfeld, MD, MA, led the ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...

On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Please provide your email address to receive an email when new articles are posted on . Delaying the need for a corneal transplant is critical in pediatric patients. Young patients must be treated ...

Keratoconus is a progressive, noninflammatory corneal disorder that causes corneal thinning and irregularity, resulting in impaired vision. It typically begins in adolescence and progresses slowly ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...